0001541157 2026-05-08 2026-05-08 0001541157 1 2026-05-08 2026-05-08 0001541157 2 2026-05-08 2026-05-08 0001541157 3 2026-05-08 2026-05-08 0001541157 4 2026-05-08 2026-05-08 0001541157 5 2026-05-08 2026-05-08 0001541157 6 2026-05-08 2026-05-08 0001541157 7 2026-05-08 2026-05-08 0001541157 8 2026-05-08 2026-05-08 0001541157 9 2026-05-08 2026-05-08 iso4217:USD pure S-1 S-1 EX-FILING FEES 0001541157 Akari Therapeutics Plc N/A N/A S-1 Akari Therapeutics Plc false Equity Ordinary shares, nominal value $0.000000005 per share ("ordinary shares"), as represented by American Depositary Shares ("ADSs") true 7500000.00 0.0001381 1035.75 false Other Pre-funded warrants to purchase ordinary shares, as represented by ADSs true 0.00 0.0001381 0.00 false Equity Ordinary shares, as represented by ADSs, issuable upon exercise of the pre-funded warrants true 0.00 0.0001381 0.00 false Other Series H common warrants to purchase ordinary shares, as represented by ADSs true 0.00 0.0001381 0.00 false Equity Ordinary shares, as represented by ADSs, issuable upon exercise of the Series H common warrants true 7500000.00 0.0001381 1035.75 false Other Series I common warrants to purchase ordinary shares, as represented by ADSs true 0.00 0.0001381 0.00 false Equity Ordinary shares, as represented by ADSs, issuable upon exercise of the Series I common warrants true 7500000.00 0.0001381 1035.75 false Other Placement agent warrants to purchase ordinary shares, as represented by ADSs true 0.00 0.0001381 0.00 false Equity Ordinary shares, as represented by ADSs, issuable upon exercise of the placement agent warrants true 281250.00 0.0001381 38.84 22781250.00 3146.09 0.00 0.00 3146.09 Security Class Title - Amount Registered: Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the ordinary shares as represented by ADSs registered hereby also include an indeterminate number of additional ordinary shares as represented by ADSs as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions. Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. The registrant may issue pre-funded warrants to purchase ordinary shares as represented by ADSs in the offering. The purchase price of each pre-funded warrant will equal the price per share at which the ADSs are being sold to the public in this offering, minus $0.001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the pre-funded warrant will equal $0.001 per ADS (subject to adjustment as provided for therein). The proposed maximum aggregate offering price of the ordinary shares as represented by ADSs will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any ordinary shares as represented by ADSs issued in the offering. Accordingly, the proposed maximum aggregate offering price of the ordinary shares as represented by ADSs and pre-funded warrants (including the ordinary shares as represented by ADSs issuable upon exercise of the pre-funded warrants), if any, is $7,500,000. No separate fee is required pursuant to Rule 457(g) of the Securities Act. The registrant may issue pre-funded warrants to purchase ordinary shares as represented by ADSs in the offering. The purchase price of each pre-funded warrant will equal the price per share at which the ADSs are being sold to the public in this offering, minus $0.001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the pre-funded warrant will equal $0.001 per ADS (subject to adjustment as provided for therein). The proposed maximum aggregate offering price of the ordinary shares as represented by ADSs will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any ordinary shares issued in the offering. Accordingly, the proposed maximum aggregate offering price of the ordinary shares as represented by ADSs and pre-funded warrants (including the ordinary shares as represented by ADSs issuable upon exercise of the pre-funded warrants), if any, is $7,500,000. No separate fee is required pursuant to Rule 457(g) of the Securities Act. No separate fee is required pursuant to Rule 457(g) of the Securities Act. No separate fee is required pursuant to Rule 457(g) of the Securities Act. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act, the proposed maximum aggregate offering price of the placement agent's warrants is $281,250, which is equal to 3.0% of the aggregate value of the ADSs to be sold in the offering at an exercise price equal to 125% of the public offering price per share.